Abstract 6131
Background
WX-0593 is a potent ALK inhibitor against ALK and ROS1 rearrangement and a series of crizotinib (CRZ)-resistant mutants. We explored the safety and efficacy of WX-0593 in patients (pts) diagnosed with ALK+ or ROS-1+ malignancies, including non-small cell lung cancer (NSCLC).
Methods
In this ongoing phase I, dose-escalation, multicenter trial (NCT03389815), 54 pts (third-grade class-A hospital confirmed ALK+ or ROS-1+) received WX-0593 (30, 60, 90, 120, 180, 240 or 300 mg) orally once daily until disease progression or unacceptable toxicity. Activity and safety were evaluated.
Results
From 25 September 2017 to 26 December 2018, 54 pts were enrolled, including 46 with ALK+ NSCLC, 10 with ROS1+ NSCLC (2 with both ALK+ and ROS1+, 38.9% with prior CRZ, 9.3% with prior CRZ and second generation ALK inhibitors). Grade 3 QTc prolongation reported in 300 mg cohort was identified as dose-limiting toxicity (DLT). Treatment-emergent adverse events (TAEs) associated with WX-0593 in > 20% of pts include: hypercholesterolemia (40.7%), nausea (40.7%), hypertension (37.0%) increased ALT (31.5%), increased AST (29.6%), hypertriglyceridemia (25.9%), hyperlipidemia (25.9%), vomiting 25.9%. Serious adverse events (SAE) occurred in 6 pts (11.1%). No treatment related death occurred. 2 pts (3.7%) had SAE related with WX-0593 treatment, including increased ALT (dose of 180 mg), increased AST (dose of 180 mg) and chronic heart failure (dose of 300 mg). For ALK+ NSCLC (n=46), objective response rate (ORR) was 29/44 (65.9%). The ORR in CRZ-naive pts was 17/21 (81.0%), 8/18 (44.4%) in CRZ pre-treated pts. ORR was 3/10 (30.0%) in ROS1+ NSCLC pts. By 26 December 2018, median progression-free survival was not reached, 39 patients remained on WX0593 treatment.Table:
1485PD Objective response rate in ALK-positive and ROS1-positive NSCLC patients
ORR, n / m (%) | 30mg N = 3 | 60mg N = 3 | 90mg N = 8 | 120mg N = 11 | 180mg N = 13 | 240mg N = 13 | 300mg N = 3 | total |
---|---|---|---|---|---|---|---|---|
ALK+NSCLC | ||||||||
all pts | 2/2 (100.0) | 2/3 (66.7) | 2/5 (40.0) | 8/10 (80.0) | 7/10 (70.0) | 7/11 (63.6) | 1/3 (33.3) | 29/44 (65.9) |
CRZ-naive pts | 2/2 (100.0) | 2/3 (66.7) | 0 | 6/7 (85.7) | 3/4 (75.0) | 3/4 (75.0) | 1/1 (100.0) | 17/21 (81.0) |
pts with prior CRZ | 0 | 0 | 2/4 (50.0) | 1/2 (50.0) | 3/5 (60.0) | 2/5 (40.0) | 0/2 | 8/18 (44.4) |
pts with prior CRZ and other ALK inhibitor | 0 | 0 | 0/1 | 1/1 (100.0) | 1/1 (100.0) | 2/2 (100.0) | 0 | 4/5 (80.0) |
ROS1+NSCLC | ||||||||
all pts | 0/1 | 0 | 1/3 (33.3%) | 0/1 | 2/3 (66.7%) | 0/2 | 0 | 3/10 (30.0%) |
Conclusions
This study revealed the antitumor activity of WX-0593 in ALK- or ROS-positive NSCLC. Safety profile was acceptable. A phase II trial to evaluate the ORR of 120 mg and 180 mg once daily is ongoing.
Clinical trial identification
NCT03389815.
Editorial acknowledgement
Legal entity responsible for the study
Qilu Pharmaceutical Co., Ltd.
Funding
Qilu Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2685 - Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
Presenter: Jhanelle E. Gray
Session: Poster Discussion – NSCLC, metastatic
Resources:
Abstract
Poster Discussion – NSCLC, metastatic - Invited Discussant 1483PD, LBA82, LBA83 and LBA84
Presenter: Federico Cappuzzo
Session: Poster Discussion – NSCLC, metastatic
Resources:
Slides
Webcast
Poster Discussion – NSCLC, metastatic - Invited Discussant 1484PD, 1485PD, 1486PD and 1487PD
Presenter: Fiona Blackhall
Session: Poster Discussion – NSCLC, metastatic
Resources:
Slides
Webcast
Poster Discussion – NSCLC, metastatic - Invited Discussant 1488PD, 1489PD, 1490PD and LBA85
Presenter: Ross Soo
Session: Poster Discussion – NSCLC, metastatic
Resources:
Slides
Webcast